The efficacy and safety of leflunomide in treating IgA nephropathy with nephrotic syndrome
Objective This article mainly discusses the efficacy and safety of leflunomide(LEF)and other immunosuppressive agents(CTX,MMF)in the treatment of IgA nephropathy with nephrotic syndrome.Methods From the pubmed,Cochrane,CNKI,CBM and other databases,six randomized controlled trial(RCT)studies on the treatment of IgA nephropathy with nephrotic syndrome as the main manifestation in the past 30 years were collected.These studies compared remission rates,changes in 24 h urine protein,serum albumin,and blood creatinine levels,and all adverse events that occurred before and after treatment.The statistical software Review Manager 5.0 was used for graph analysis to determine the 95%confidence interval.Results In terms of remission rate,24 h urine protein,and blood creatinine levels:no significant differences were observed between the LEF group and the control group;Serum albumin level:albumin was elevated in all patients in the LEF-treated group compared with the control group,but the difference in elevation was statistically significant in the LEF-treated group;adverse reactions:The LEF treatment group had fewer adverse reactions compared to the control group,and the difference was statistically significant.Conclusion According to our current research,LEF treatment of nephrotic syndrome with IgA nephropathy is as effective as CTX/MMF,and it is more helpful for patients to improve albumin levels after treatment,and the adverse reactions are relatively smaller.
NETL
NSTL
万方数据
